Brief: Tiziana Life Sciences Files New Patent Application for Combination Therapy of Anti-CD3 With GLP-1 Receptor Agonist
05/01/2024 12:09
Jan 5 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES FILES NEW PATENT APPLICATION FOR
COMBINATION THERAPY OF ANTI-CD3 (FORALUMAB) WITH GLP-1 RECEPTOR
AGONIST FOR ADDITIONAL REDUCTION OF OBESITY - ASSOCIATED
INFLAMMATION
Source text for Eikon: ID:nGNX5jLFVN
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study